Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Enclomiphene and MENT Interaction: Synergistic | Peptide Database

Compound Profiles Enclomiphene Selective Estrogen Receptor Modulator | Testosterone & Fertility Support Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH re

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

MENT

19-Nor Anabolic Steroid | Experimental TRT Alternative

MENT binds to the androgen receptor with high affinity, estimated at roughly 10 times the potency of testosterone, driving robust activation of AR-dependent gene transcription pathways responsible for protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Its 7-alpha methyl group renders it resistant to 5-alpha reductase, meaning it is not converted to a reduced metabolite in androgen-sensitive tissues the way testosterone is converted to DHT or nandrolone is converted to DHN.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Enclomiphene with MENT?

Yes, Enclomiphene and MENT can generally be taken together. MENT supports hormonal recovery from suppression caused by Enclomiphene. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.

Is Enclomiphene and MENT safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: teratogenic. Monitor accordingly.

What are the interactions between Enclomiphene and MENT?

MENT supports hormonal recovery from suppression caused by Enclomiphene. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and MENT?

Enclomiphene has a half-life of ~10 hours and MENT has a half-life of ~40 minutes (acetate ester). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Pancragen — share findings, ask questions, and learn from real experiences Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances. Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures to modulate pancreatic gene expression. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Its small size (4 amino acids, ~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA.

Source: peptide-db.com ↗

Research Indications

GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction. Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%). Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits. HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%. 48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide. Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials. Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Raloxifene is administered orally as a tablet (raloxifene hydrochloride). It has approximately 60% oral absorption, though extensive first-pass glucuronidation results in an absolute bioavailability of about 2%. Despite the low bioavailability, the 60mg dose produces reliable clinical effects. Peak plasma concentrations are reached within 0.5-6 hours. The 28-hour half-life supports once-daily dosing. Can be taken with or without food. Gynecomastia reversal 60mg Once daily for 3-6 months Oral On-cycle gynecomastia prevention Once daily throughout cycle Osteoporosis prevention/treatment (medical) Once daily

Source: peptide-db.com ↗
Side effects

Common Side Effects

Headache (most frequently reported side effect, often dose-dependent) Insomnia (particularly if taken too late in the day) Anxiety and nervousness Appetite suppression and mild nausea Dry mouth Dizziness Gastrointestinal discomfort (diarrhea, abdominal pain)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →